Literature DB >> 10363875

Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.

D W Sundlof1, P Rerkpattanapitat, N Wongpraparut, P Pathi, M N Kotler, L E Jacobs, G S Ledley, S Yazdanfar.   

Abstract

The use of abciximab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10363875     DOI： 10.1016/s0002-9149(99)00151-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  3 in total

Review 1.  Glycoprotein IIb/IIIa Inhibition as an adjunct to rescue angioplasty after failed fibrinolysis.

Authors:  J A Sallach; A B Greenbaum
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

2.  Predictors of bleeding complications after rescue coronary interventions.

Authors:  H L Dauerman; C Andreou; M A Perras; J S Spinner; D Lessard; B H Weiner
Journal:  J Thromb Thrombolysis       Date:  2000-08       Impact factor: 2.300

Review 3.  Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target.

Authors:  Melanie Ziegler; Xiaowei Wang; Karlheinz Peter
Journal:  Cardiovasc Res       Date:  2019-06-01       Impact factor: 10.787
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.